# Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

> **NCT07500298** · PHASE1 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 41 (estimated)

## Conditions studied

- Phase 1
- SAR445877
- FOlfox6
- Bevacizimab
- First Line Treatment
- Metastatic Colorectal Cancer (CRC)
- Microsatellite Stable

## Interventions

- **DRUG:** SAR445877
- **DRUG:** FOLFOX6
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07500298
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-03
- **Primary completion:** 2030-12-27
- **Final completion:** 2032-12-27
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07500298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07500298, "Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07500298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*